INREBIC Celgene Pty Ltd
Product name
INREBIC
Sponsor
Accepted date
Feb-2024
Active ingredients
fedratinib
Proposed indication
Indicated for the treatment of disease-related splenomegaly.
Application type
A (new medicine)
Publication date
Feb-2024